Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Document › Details

Minoryx Therapeutics S.L.. (2/20/18). "Press Release: Minoryx Therapeutics Spins Off SEE-Tx Platform into New Company, Gain Therapeutics". Mataró, Barcelona & Lugano.

Organisations Organisation Minoryx Therapeutics S.L.
  Organisation 2 Gain Therapeutics (CH)
  Group Gain Therapeutics (Group)
Products Product SEE-Tx platform (Site-directed Enzyme Enhancement Therapy platform
  Product 2 venture capital
Index term Index term Gain Therapeutics–SEVERAL: investment, 201802 investment spin-off of Minorix’ SEE-Tx platform as Gain Therapeutics with Swiss investors + TiVenture
Persons Person Barril, Xavier (Gain Therapeutics 201802 CSO before Minoryx Therapeutics + Vernalis)
  Person 2 Leoni, Lorenzo (TiVenture Fund 201802 Managing Director + Gain Therapeutics 201802– interim CEO before Telormedix)
     


The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril


Minoryx Therapeutics and Gain Therapeutics announce today the spin off of the Minoryx Site-directed Enzyme Enhancement Therapy (SEE-Tx) platform into Gain Therapeutics, a new company that will focus on using this platform to identify the next generation of non-competitive pharmacological chaperones.

Gain Therapeutics, funded by private Swiss investors and by the TiVenture fund has its headquarters in Lugano (Switzerland), with a branch operating from Barcelona (Spain). Researchers from the Minoryx laboratory at the Barcelona Science Park joined the new spin-off, under the scientific management of Dr Xavier Barril, ICREA researcher and co-founder of Minoryx Therapeutics, inventor of the technology.

This new spin-off is part of Minoryx’s business strategy, in order to concentrate the company’s efforts on the clinical candidate MIN-102.

“This deal validates the SEE-Tx platform and its great potential for identifying a new generation of pharmacological chaperones with improved properties,” said Dr Marc Martinell, co-founder and CEO of Minoryx Therapeutics. “It will also allow Minoryx to focus on its clinical candidate, MIN-102, which is now in phase II/III clinical trials for the treatment of X-linked adrenoleukodystrophy and in preclinical development for other orphan CNS diseases.”

“We are delighted to build on the excellent work done by Minoryx’s team. Using the SEE-Tx platform, it has already identified molecules that have the potential to become novel therapies for the treatment of several devastating rare diseases,” said Dr Lorenzo Leoni, managing partner of TiVenture and ad-interim CEO of Gain Therapeutics. “We will invest in the further development of these molecules that should lead to the identification of clinical candidates in at least two independent programs. We are also happy to strengthen the cooperation between Barcelona and southern Switzerland, two regions with high innovation potential in the biomedical field.”


About the SEE-Tx platform

Within personalized medicine, pharmacological chaperones are one of the therapeutic approaches of the future, with significant advantages over other treatments for rare metabolic diseases. This approach is based on using small molecules with a good pharmacokinetic profile to rescue mutated proteins whose loss of function is at the root of many rare diseases.

The technology developed by Minoryx, now licensed to Gain Therapeutics, uses the three-dimensional structure of proteins originating from a patented computational technology initially discovered by the Barril Lab, University of Barcelona. “With this innovative technological platform we can discover improved pharmacological chaperones for rare genetic diseases with a high unmet medical need,” said Dr Barril.


About Gain Therapeutics

Gain Therapeutics (www.gaintherapeutics.com) is a preclinical stage biotech company developing a class of next generation pharmacological chaperones for the treatment of devastating rare diseases using the SEE-Tx technology. The company has five discovery programs at various stages of development, all of which validate the platform and offer significant partnering opportunities. Gain Therapeutics was established in 2017 by experienced biotech entrepreneurs. It is financed by TiVenture (www.tiventure.ch), a seed and early stage venture capital fund investing in technology-driven companies in southern Switzerland belonging to the Fondazione Centenario BancaStato.


About Minoryx Therapeutics

Minoryx is a clinical stage biotech company leading the development of new therapies for X-linked Adrenoleukodystrophy (X-ALD) and other inborn errors of metabolism, a group of rare diseases of genetic origin with a high unmet medical need. The company’s leading program is MIN-102, which has multiple CNS indications beyond X-ALD. The Minoryx team is made up of a group of drug discovery and development experts with several decades of experience in biotech and pharma. The company is backed by a syndicate of experienced investors and has support from a network of other organizations. Minoryx was founded in 2011 and has to date raised a total of €24.4M.

www.minoryx.com


Media Contacts & Analysts

Andrew Lloyd & Associates
Agnes Stephens – Sandra Régnavaque
agnes@ala.com / sandra@ala.com
@ALA_Group
+ 44 1273 675 100

   
Record changed: 2018-03-02

Advertisement

Picture EBD Group Bio-Europe 2018 Copenhagen Denmark November 600x60px

More documents for Minoryx Therapeutics S.L.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnering Open 600x60px




» top